Prof Hochhaus
Hehlmann R et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34(8):2074-86. Abstract
Hochhaus A et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 2024;391(10):885-98. Abstract
Hochhaus A et al. Nilotinib vs nilotinib + peg-interferon alpha induction and nilotinib or peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. The TIGER trial. EHA 2023;Abstract S157.
Hughes TP et al. ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results. ASCO 2024;Abstract LBA6500.
Hughes TP et al. Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis. ASH 2019;Abstract 2924.
Kantarjian HM et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35(2):440-53. Abstract
La Rosée P et al. Improved tolerability with dasatinib 5 days compared to 7 days per week in patients with chronic myeloid leukemia in chronic phase. Final results of the DasaHIT trial. EHA 2024;Abstract S172.
Schönfeld L et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia 2022;36(9):2242-9. Abstract
Yeung DT et al. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: Results from the ASCEND study. Blood 2024;144(19):1993-2001. Abstract
Dr Mauro
Cortes JE et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 2024;38(7):1522-33. Abstract
Cortes JE et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: Final 5-year results of the phase 2 PACE trial. Blood 2018;132(4):393-404. Abstract
Jabbour E et al. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA 2024;331(21):1814-23. Abstract
Mauro M et al. Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population. ASH 2023;Abstract 4536.
Dr Smith
Bower H et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34(24):2851-7. Abstract
Cortes JE et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34(20):2333-40. Abstract
Druker BJ et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17. Abstract
Efficace F et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27(7):1511-9. Abstract
Larson RA et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26(10):2197-203. Abstract